Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma ("Nxera"; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse's generative AI antibody design expertise, including its proprietary machine-learning-generated 'epitope-specific libr ...